Fig. 2

EVT901 treatment inhibited the inflammatory response to LPS in isolated leukocytes in vitro. The isolated leukocytes (1 × 10⁶ cells) were treated with 10 ng/ml LPS, LPS + EVT901 (30 nM), EVT901, or vehicle. After 24-h incubation at 37 °C, cells were isolated by centrifugation and the cell type identified by flow cytometry. a CD11b + Ly6C+ monocytes consisted of two distinct subpopulations: Ly6C^low monocytes and Ly6C^int-high pro-inflammatory monocytes. b–d LPS treatment increased the proportion of the population that was the CD11b + Ly6C^int-high, while EVT901 treatment reduced it. Data were obtained from three independent experiments. One-way ANOVA showed a significant effect of condition (F _4,14 = 7.03, p = 0.007, η ² = 0.76, power = 0.92; Tukey’s post hoc test, *p < 0.05, **p < 0.005). e TNFα in the supernatant was measured using ELISA. EVT901 treatment inhibited TNFα production by LPS. Data were obtained from three independent experiments. One-way ANOVA showed a significant effect of condition (F _4,15 = 13.81, p = 0.0004, η ² = 0.85, power = 0.999; Tukey’s post hoc tests,*p < 0.05, ^## p < 0.001)